What is the clinical activity of combining the tumor-targeting interleukin 12 antibody-drug conjugate PDS01ADC, the bifunctional anti–programmed cell death ligand 1 (PD-L1)/transforming growth factor β (TGF-β) bintrafusp alfa, and the human papillomavirus (HPV) type 16 therapeutic vaccine PDS0101 in adult patients with advanced HPV-associated cancers? This evidence concerns the gene TGFB1 and cancer.